Created by Joyce Soh
Latest lupus research, treatment updates, practical management tips, and patient stories
Explore the latest content tracked by Lupus Insight Hub
A new study by PJ Hoover uses deep profiling of lupus nephritis kidneys to uncover dynamic immune responses in this common, potentially fatal SLE manifestation. The work targets fresh insights that could inform more precise therapies.
At 14, Nicholas lives with lupus-driven fatigue that reshapes childhood. A new non-invasive brain imaging study now targets the roots of cognitive dysfunction in children and teens with the disease.
Pregnancies in patients with autoimmune diseases like lupus carry increased maternal and fetal risks. Autologous CD19-targeted therapies are emerging as a key treatment option in this context.
Patients often forget specific procedures but remember how they felt during a trial. Clear explanations, patient questions answered with patience, and...
New studies reveal SLE patients face substantial extra burdens beyond core disease activity.
The Lupus Nexus registry and biorepository offers researchers access to longitudinal data, linked biospecimens, and omics from up to 3,500 lupus...
Anifrolumab shows efficacy against lupus-related autoimmune haemolytic anemia in the first reported case. This marks a potential new option for a challenging complication.
GLP-1 medications may help lupus patients by calming the immune system and reducing inflammation, potentially counteracting several damaging effects. The hypothesis remains at an early stage.
Orelabrutinib 75 mg delivered clear benefits in a Phase IIb trial as a potential oral targeted therapy for moderate-to-severe SLE.
AbelZeta Pharma gained FDA clearance under its RMAT designation for a registrational Phase II trial of C-CAR168, a bispecific anti-CD20/BCMA CAR-T, in...
Lupus inflammatory signals reprogram neutrophils, shifting them from effective antibacterial NETosis to a weaker form after failing to sense bacterial...
Reduced serum Sestrin-1 is associated with subclinical cardiovascular risk in lupus patients, even without overt clinical disease. This connection underscores the value of early detection for heart complications in SLE.
Serum IL-32γ stands out as a novel biomarker for SLE remission, correlating with disease activity and uniquely retaining discriminatory power for stringent states like DORIS and glucocorticoid-free remission where other markers fall short.
No significant updates today.
Lupus patients require year-round sun protection as treatment guidelines now embrace treat-to-target for real remission, enabling warriors to thrive rather than just survive.
A UCLA team led by Lili Yang received a $7.49 million CIRM grant to develop a universal CAR-NKT cell therapy targeting MS. Key advantages include dual...
Reduced C3 levels directly connect dyslipidemia to renal involvement in lupus, underscoring complement activation as a driver of lupus nephritis progression.
Skin manifestations often serve as the first visible signs of systemic autoimmune diseases like lupus. Recognizing patterns such as photosensitive...
